Trial Profile
A Phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of the IV liposomal formulation of ibrexafungerp in healthy subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Ibrexafungerp (Primary)
- Indications Candidiasis; Invasive bronchopulmonary aspergillosis; Pneumocystis pneumonia; Vulvovaginal candidiasis
- Focus Adverse reactions; Pharmacokinetics
- 29 Mar 2022 According to a SCYNEXIS media release, the last cohort of study completed in October 2021.
- 09 Nov 2021 Results published in the a SCYNEXIS Media Release
- 09 Nov 2021 Status changed from recruiting to completed, according to a SCYNEXIS media release.